Choose your location:

Choose a Language

Contact us

Press Releases

Content of this page is intended for journalists and investors only.

17 May 2023

Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases

Ipsen ESPGHAN congress 052023
27 April 2023

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

Q1 2023 – Sales announcement

Q1 2023 – Sales presentation

Q1 2023 – Webcast replay

24 April 2023

Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs

Ipsen CMO Announcement Press Release

Sandra Silvestri Photo
06 April 2023

Ipsen publishes its 2022 Universal Registration Document

Ipsen publishes its 2022 Universal Registration Document
16 March 2023

Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP

Ipsen_Palovarotene New PDUFA Date_032023
02 March 2023

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

Ipsen completes acquisition of Albireo – Press Release – 03-23
22 February 2023

Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023

Ipsen – Press Release Announcing Extension of Tender Offer for Albireo
15 February 2023

Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs

Ipsen-IRICoR-Press-Release-02-2023
13 February 2023

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

ASCO-GU-press-release-02132023-corrected
09 February 2023

Ipsen presents strong full-year 2022 results and guidance for 2023

FY 2022 – Results announcement

FY 2022 – Results presentation

FY 2022 – Results webcast
27 January 2023

Ipsen receives CHMP negative opinion for palovarotene as a treatment for fibrodysplasia ossificans progressiva in E.U.

Ipsen Palovarotene CHMP Opinion Press Release 01-2023
20 January 2023

Ipsen presents Phase III NAPOLI 3 trial of Onivyde® regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI

Ipsen NAPOLI 3 Phase III Press Release 01-2023
09 January 2023

Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases

Ipsen to acquire Albireo: announcement

Ipsen to acquire Albireo: presentation
23 December 2022

Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva

Ipsen-Palovarotene-FDA-CRL-Press Release-12-2022
14 December 2022

Ipsen demonstrates commitment to innovation in neuroscience at 12th World Congress for Neurorehabilitation (WCNR)

Ipsen-WCNR-Press-Release-12-2022-14
08 December 2022

Ipsen provides update on Phase III CONTACT-01 trial evaluating cabozantinib in combination with atezolizumab in patients with metastatic non-small cell lung cancer previously treated with immunotherapy and chemotherapy

Ipsen-Contact-Press-Release-12-2022
09 November 2022

Onivyde® regimen demonstrated statistically significant improvement in overall survival in previously untreated metastatic pancreatic ductal adenocarcinoma

Ipsen Onivyde Press Release 11-2022
27 October 2022

Ipsen delivers strong sales growth in the first nine months of 2022 and confirms its full-year guidance

YTD 2022 – Sales announcement

YTD 2022 – Sales presentation

YTD 2022 – Webcast
25 October 2022

Ipsen statement on updated timeline for palovarotene FDA Advisory Committee meeting

Ipsen statement on updated timeline for palovarotene FDA Advisory Committee meeting
28 September 2022

Ipsen’s global Natural History Study of Fibrodysplasia Ossificans Progressiva shows debilitating impact of the disease over an individual’s lifetime

Ipsen NHS of FOP – September 2022
05 September 2022

First international Fibrodysplasia Ossificans Progressiva (FOP) Burden of Illness Survey reveals extent of social, economic, and quality of life impact of disease

Ipsen BOI Manuscript Press Release 09_22
12 August 2022

Ipsen completes acquisition of Epizyme expanding its portfolio in oncology

Ipsen completes acquisition of Epizyme – 12 August 2022
05 August 2022

Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022

Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022
03 August 2022

Ipsen announces results from Phase III RESILIENT trial evaluating Onivyde® in second-line monotherapy for small cell lung cancer

Ipsen Onivyde Press Release – August 2022
01 August 2022

Ipsen and Marengo Therapeutics announce strategic partnership to advance two precision immuno-oncology candidates from Marengo’s STAR Platform into the clinic

Ipsen Marengo Press Release
01 August 2022

Ipsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV Discovery

Ipsen AGV DISCOVERY Press Release
28 July 2022

Ipsen delivers strong H1 2022 results and upgrades its full-year guidance

Ipsen – H1 2022 – Results announcement

Ipsen – H1 2022 – Results presentation

Ipsen - H1 2022 - Results webcast
29 June 2022

Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission

Ipsen FDA Priority Review for palovarotene NDA
27 June 2022

Ipsen to acquire Epizyme, expanding its portfolio in oncology

Ipsen to acquire Epizyme expanding its portfolio in oncology

Acquisition of Epizyme

Webcast Acquisition of Epizyme
09 June 2022

Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or spinal cord injury

Ipsen – Dysport Positive Opinion Europe 2022
01 June 2022

Ipsen initiates a share buy-back program to cover its employee free share-allocation plan

Ipsen initiates a share buy-back program to cover its employee free share-allocation plan
27 May 2022

ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and in combination across different tumor types including metastatic non-small cell lung cancer

Ipsen ASCO annual meeting press release ENG FINAL
03 May 2022

European Commission approves Cabometyx® as a second-line treatment for people living with radioactive iodine-refractory differentiated thyroid cancer

Ipsen_DTC EC approval_ENG
27 April 2022

Ipsen delivers a strong sales performance in the first quarter of 2022

Q1 2022 – Sales announcement

Q1 2022 – Sales presentation

Webcast Q1 2022
25 March 2022

Ipsen receives positive CHMP opinion for Cabometyx® in radioactive iodine-refractory differentiated thyroid cancer

Ipsen – DTC CHMP – 25 March 2022
16 March 2022

Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) designed to improve patient experience

Ipsen – Somatuline Autogel Depot Electronic Autoinjector – 16 March 2022
08 March 2022

New patient-reported data demonstrated high satisfaction levels and fewer patients reporting injection-site pain with Somatuline® Autogel®/Somatuline® Depot (lanreotide)

Ipsen_ENETS 2022_ENG
16 February 2022

Ipsen appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen – Nomination of Catherine Abi Habib EVP Strategy Transformation Digital – 16 February 2022
15 February 2022

Cabometyx® in combination with Opdivo® demonstrated continued survival and quality of life benefits with over two years of follow-up in the Phase III CheckMate -9ER trial

Ipsen – ASCO GU – 15 February 2022
11 February 2022

Ipsen presents strong full-year 2021 results and enters into exclusive negotiations to divest its Consumer Healthcare business

FY 2021 – Results announcement

FY 2021 - Results presentation

Webcast replay FY 2021
24 January 2022

Health Canada approves Ipsen’s Sohonos (palovarotene capsules) as the first approved treatment for fibrodysplasia ossificans progressiva

Ipsen – Health Canada approves Ipsen’s Sohonos (palovarotene capsules) – 24 January 2022
21 January 2022

Ipsen nominates Karen Witts as new independent Board member

Ipsen – Nomination of Karen Witts as new independent Board member – 21 January 2022
17 December 2021

Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

Ipsen – Genfit Collaboration – 17 December 2021

Ipsen Expanding the scope in Rare Disease
27 October 2021

Ipsen Pledges Ambitious Action on Climate Change

ENG — Press Release – Ipsen Pledge to Climate 27102021_FINAL
21 October 2021

Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance

YTD 2021 – Sales announcement

YTD 2021 – Sales presentation

Webcast replay Q3
18 October 2021

Ipsen adds another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3

Ipsen – Accent collaboration – 18 October 2021
11 October 2021

Ipsen appoints Mari Scheiffele as EVP and President, Specialty Care International

Ipsen – Appointment of Mari Scheiffele – 11 October 2021
18 September 2021

ESMO 2021: Cabometyx® demonstrates sustained 78% reduction in risk of disease progression or death in people living with uncommon form of thyroid cancer

Ipsen – ESMO 2021 – 18 February 2021
13 August 2021

Ipsen announces withdrawal of palovarotene NDA, confirming intention to re-submit following additional data analyses

Ipsen_Palovarotene NDA withdrawal_13 August
02 August 2021

Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders

Ipsen-Exicure collaboration-2 August 2021
29 July 2021

Ipsen delivers strong H1 2021 results and upgrades full-year guidance

H1 2021 – Results announcement

H1 2021 – Results presentation

Webcast replay H1
27 July 2021

Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway

Ipsen-BAKX collaboration-27 July 2021
15 July 2021

Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease

Ipsen – IRLAB – 15 July 2021
28 June 2021

Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer

Ipsen – Exelixis COSMIC-312 – 28 June 2021
07 June 2021

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Ipsen – Exelixis COSMIC-311 ASCO – 7 June 2021
02 June 2021

Ipsen initiates a share buy-back program to cover its performance and employee share plans

Ipsen initiates a share buy-back program to cover its performance and employee share plans
01 June 2021

Ipsen announces the launch of an Employee Shareholding Plan

Ipsen announces the launch of an Employee Shareholding Plan
28 May 2021

Ipsen confirms U.S. FDA accepts New Drug Application for palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP)

Ipsen – Palovarotene FDA acceptance – 28 May 2021
19 May 2021

Information relating to the composition of the bureau – 2021 Ipsen Combined Shareholder’s Meeting

Information relating to the composition of the bureau – 2021 Ipsen Combined Shareholder’s Meeting
11 May 2021

Ipsen opts-in to join Exelixis with ongoing development of Cabometyx® for people living with a form of thyroid cancer, based on promising interim results

Ipsen opts-in to join Exelixis with ongoing development of Cabometyx® for people living with a form of thyroid cancer, based on promising interim results
22 April 2021

Ipsen delivers encouraging sales growth in the first quarter of 2021 despite the pandemic, and confirms its full-year guidance

Q1 2021 – Sales announcement

Q1 2021 – Sales presentation

Webcast replay Q1
15 April 2021

Ipsen publishes its 2020 Universal Registration Document

Universal registration document 2020 – AMF deposit
31 March 2021

European Commission approves Cabometyx® in combination with Opdivo® as a first-line treatment for patients living with advanced renal cell carcinoma

Ipsen – Cabometyx Opdivo EMA Release – 31 March 2021
26 February 2021

Ipsen receives positive CHMP opinion recommending Cabometyx® in combination with Opdivo® as first-line treatment for patients living with advanced renal cell carcinoma

Ipsen – CHMP release – 26 February 2021
22 February 2021

Ipsen announces new data from the Phase II CLARINET FORTE study which demonstrated preservation of quality of life when increasing dose frequencies of Somatuline® Autogel® (lanreotide)

Ipsen – ENETS 2021 – 22 February 2021
11 February 2021

Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021

FY 2020 – Results announcement

FY 2020 – Results presentation
08 February 2021

New data from pivotal Phase III CheckMate -9ER trial of Cabometyx® in combination with Opdivo® showed significantly improved QoL benefits and sustained superior efficacy versus sunitinib in patients living with aRCC

Ipsen – ASCO GU 2021 – 8 February 2021
05 February 2021

Ipsen to showcase commitment to going beyond traditional outcome measures for patients living with renal cell carcinoma at ASCO GU 2021

Ipsen – ASCO GU 2021 – 5 February 2021
20 January 2021

Ipsen appoints Gwenan White as Executive Vice President, Communications and Public Affairs

Ipsen – Gwenan White nomation – 20 January 2021
15 January 2021

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications

Ipsen – TOXINS 2021 – 15 January 2021
01 December 2020

Ipsen highlights new strategic priorities and provides mid-term financial outlook

Capital Market Day 2020 – Announcement
30 November 2020

Ipsen receives FDA Fast Track designation for investigational irinotecan liposome injection (ONIVYDE®) as a second-line monotherapy treatment for small cell lung cancer (SCLC)

Ipsen – Onivyde FDA Fast Track – 30 November 2020
22 October 2020

Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance

YTD 2020 – Sales announcement

YTD 2020 – Sales presentation
08 October 2020

Ipsen to present 12 abstracts at the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress taking place jointly with the 35th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER)

Ipsen – WCNR Curtain Raiser – 8 October 2020
25 September 2020

Ipsen appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer

Ipsen – ELT appointment – 25 September 2020
19 September 2020

ESMO 2020: Cabometyx® (cabozantinib) in combination with Opdivo® (nivolumab) demonstrates significant survival benefits in patients with advanced renal cell carcinoma in pivotal Phase III CheckMate -9ER trial

Ipsen – ESMO 2020 CheckMate9ER – 19 September 2020
18 September 2020

ESMO 2020: Phase II CLARINET FORTE results show increasing dose frequencies of Somatuline® Autogel® (lanreotide) allows patients with NETs to delay treatment escalation by up to 8.3 months

Ipsen – ESMO 2020 CLARINET FORTE release – 18 September 2020
14 September 2020

Ipsen showcases commitment to patient-centric advances in oncology with record number of abstracts to be presented at ESMO 2020 Virtual Congress

Ipsen – ESMO 2020 curtain raiser – 14 September 2020
10 September 2020

Ipsen to present new insights at ASBMR for potential treatment of ultra-rare disease fibrodysplasia ossificans progressiva (FOP), including global Phase III MOVE trial results

Ipsen – ASBMR 2020 – 10 September 2020
25 August 2020

Ipsen to present results from MOVE, the first global Phase III trial in fibrodysplasia ossificans progressiva (FOP), at ASBMR 2020 annual meeting

Ipsen – Global media release MOVE – 25 August 2020
30 July 2020

Ipsen presents its half year 2020 results and reinstates guidance for full year 2020

H1 2020 – Results annoucement

H1 2020 – Results presentation
02 July 2020

Ipsen joins clinical collaboration to evaluate cabozantinib (CABOMETYX®) plus atezolizumab in metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer

Ipsen – Clinical collaboration to evaluate Cabometyx – 2 July 2020
01 July 2020

Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde®) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer

Ipsen – ESMO GI 2020 – 1 July 2020
17 June 2020

Ipsen receives FDA Fast Track designation for liposomal irinotecan (ONIVYDE®) as a first-line combination treatment for metastatic pancreatic cancer

Ipsen – ONIVYDE FDA Fast Track – 17 June 2020
08 June 2020

Ipsen demonstrates continued commitment to rare diseases with eight abstracts accepted at ENDO 2020 published in the Journal of the Endocrine Society

Ipsen – ENDO 2020 – 8 June 2020
08 June 2020

Ipsen initiates a share buyback program to cover its share allocation plan

28 May 2020

Ipsen appoints David Loew as Chief Executive Officer

Ipsen – David Loew CEO appointment – 28 May 2020
23 May 2020

New surveys show over 80% of patients with spasticity and cervical dystonia treated with botulinum toxin-A experience debilitating symptom recurrence

Ipsen – Carenity 2020 – 23 May 2020

Ipsen – Carenity inforgraphic – 23 May 2020

Ipsen – Carenity Cervical Dystonia inforgraphic – 23 May 2020
19 May 2020

Ipsen announces publication of first matching-adjusted indirect comparison of Cabometyx® (cabozantinib) versus regorafenib in advanced hepatocellular carcinoma in Advances in Therapy

Ipsen – MAIC – 19 May 2020
04 May 2020

Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program

Ipsen – IRICOR – 4 May 2020
22 April 2020

Ipsen reports solid sales growth in first quarter 2020 with limited COVID-19 impact

Q1 2020 – Sales announcement

Q1 2020 – Sales presentation
20 April 2020

Ipsen announces positive topline results from pivotal Phase III CheckMate -9ER trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) in previously untreated advanced renal cell carcinoma

Ipsen – CheckMate9ER – 20 April 2020
01 April 2020

Ipsen donates €2 million to the Institut Pasteur to support research on COVID-19

Ipsen – Institut Pasteur – 1 April 2020
26 March 2020

Ipsen provides update on palovarotene clinical programs

Ipsen – Palovarotene Update – 26 March 2020
25 March 2020

Ipsen provides COVID-19 update

Ipsen – COVID-19 Update – 25 March 2020
11 March 2020

Ipsen data presented during ENETS Annual Conference 2020 capture new patient and healthcare professional insights in the treatment of NETs and acromegaly

Ipsen – ENETS 2020 – 11 March 2020
13 February 2020

Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook

FY 2019 – Results announcement

FY 2019 – Results presentation
24 January 2020

Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria

Ipsen – Palovarotene – 24 January 2020
14 January 2020

Ipsen appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer

Ipsen – Steven Hildemann appointment – 14 January 2020
06 January 2020

Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy

Ipsen – Dysport – 6 January 2020
18 December 2019

Ipsen Announces Departure of David Meek as Chief Executive Officer

David_Meek-News_Release_171219_EN
06 December 2019

Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies

Palovarotene_FDA_Partial_Clinical_Hold-News_Release_061219
05 November 2019

Ipsen appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development

HeadR&D-News-Release-EN
05 November 2019

Proposed reclassification of Ipsen shares held by Mayroy

NewsRelease-Mayroy-EN
31 October 2019

Ipsen presents new analyses utilizing modern data mining approaches at ISPOR Europe 2019

Ipsen ISPOR Europe curtain raiser_EN
24 October 2019

Ipsen delivers strong double-digit sales growth for the third quarter of 2019 and confirms full year 2019 guidance

YTD 2019 – Sales announcement

YTD 2019 – Sales presentation
16 October 2019

Ipsen and Blueprint Medicines announce exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP)

Download
26 September 2019

Ipsen showcases studies at the ESMO 2019 Congress highlighting progress in new approaches for difficult-to-treat cancers
23 September 2019

Ipsen announces positive results from Phase IIIb/IV ENGAGE study of the combination of Dysport® (abobotulinumtoxinA) with Guided Self-rehabilitation Contracts in adult patients with upper and lower limb spastic hemiparesis

20 September 2019

Ipsen to present new data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019)

Ipsen ILCA MAIC Press Release_EN
08 September 2019

Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer

SEPT19_Ipsen Onivyde SCLC World Lung Press Release FINAL_EN
25 July 2019

Ipsen delivers strong results for the first half of 2019 with robust double-digit sales growth and improved Core Operating margin and upgrades its guidance for full year 2019

H1 2019 – Results announcement

H1 2019 – Results presentation
05 July 2019

Ipsen and Servier announce initial Phase 1/2 clinical data evaluating liposomal irinotecan (ONIVYDE®) as an investigational first-line treatment for metastatic pancreatic cancer at ESMO 21st World Congress on Gastrointestinal Cancer

190705_Ipsen Onivyde 1st Line World GI Data Presentation Press Release ENGLISH FINAL
25 June 2019

Disclosure of transactions in own shares between 18/06/2019 and 21/06/2019

Download
18 June 2019

Ipsen initiates a share buyback program to cover its new free share allocation plan

Download
12 June 2019

Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years

Debiopharm and Ipsen agreement renewal
24 May 2019

New investigational clinical data for Ipsen’s oncology products in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting

190522-Ipsen-Oncology-ASCO-Curtain-Raiser
14 May 2019

Ipsen to host an Investor Day to highlight its innovative R&D pipeline and provide financial outlook for 2022

Press release

Ipsen -Investor-Day-2019
24 April 2019

Ipsen reports strong double-digit sales growth in First Quarter 2019 and confirms Full Year 2019 financial targets

Q1 2019 – Sales announcement

Q1 2019 – Sales presentation
18 April 2019

Ipsen Completes Acquisition of Clementia Pharmaceuticals

Download
12 April 2019

Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.

09 April 2019

Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A.

27 March 2019

Ipsen publishes its 2018 Registration Document

Download
06 March 2019

Ipsen to Present Improvements to Somatuline® Autogel® Pre-filled Syringe at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference

ENG-Ipsen_ENETS_Abstract_FINAL
28 February 2019

Ipsen to Present New Data on Enhancement of Patient Care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference

ENG-Ipsen_ENETS_CR_FINAL
25 February 2019

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio

Ipsen-to-acquire-Clementia-Final

Ipsen-to-acquire-Clementia1
14 February 2019

Ipsen delivers strong 2018 results and expects continued sales and profit growth in 2019

FY 2018 – Results announcement

FY 2018 – Results presentation
18 January 2019

Patients living with spasticity want long-lasting symptom relief

Carenity-Infographic_180119
17 January 2019

Ipsen presents the results of the first in-human study of a recombinant fast-acting neurotoxin (rBoNT-E) at TOXINS 2019

11 January 2019

Ipsen demonstrates leadership position in neurotoxin research with strong presence at TOXINS 2019

05 December 2018

Exelixis and Ipsen initiate phase 3 pivotal trial (COSMIC-312) of cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced hepatocellular carcinoma

20 November 2018

Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)

15 November 2018

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib

25 October 2018

Ipsen delivers strong sales growth of 20.2% for the third quarter of 2018 and confirms full year guidance

YTD 2018 – Sales announcement

YTD 2018 – Sales presentation
12 October 2018

Ipsen to present new data from its oncology portfolio at the 2018 European Society for Medical Oncology (ESMO) congress

21 September 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the second-line treatment of patients with hepatocellular carcinoma (HCC)

21 September 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the second-line treatment of patients with hepatocellular carcinoma (HCC)

26 July 2018

Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% and upgrades its guidance for full year 2018

HY 2018 – Results announcement

HY 2018 – Results presentation
19 July 2018

Ipsen and BioLabs to open new Innovation Center in Cambridge (U.S.) to foster development of new therapies for patients

04 July 2018

Ipsen announces new clinical data to be presented at ISPRM 2018 demonstrating commitment to neurotoxin research

04 July 2018

Ipsen announces CELESTIAL phase 3 pivotal trial results in the New England Journal of Medicine

04 June 2018

Ipsen initiates a share buyback program to cover its free share allocation and employee share plans

30 May 2018

Combined Shareholders’ Meeting of 30 May 2018

30 May 2018

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at the Combined Shareholders’ Meeting on 30 May 2018

29 May 2018

Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer

29 May 2018

Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership

17 May 2018

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma

26 April 2018

Ipsen reports strong first quarter 2018 sales growth of 23.1% at constant exchange rates

Q1 2018 – Sales announcement

Q1 2018 – Sales presentation
28 March 2018

Ipsen announces EMA validation of filing of a new application for additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).

26 March 2018

Ipsen publishes its 2017 Registration Document

23 March 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma

13 March 2018

Ipsen appoints Ivana Magovčević-Liebisch Ph.D., J.D. and Régis Mulot to Executive Leadership Team

06 March 2018

Ipsen announces 18 posters to be presented at the 15th Annual ENETS Conference

21 February 2018

Arix Bioscience and Ipsen sign a strategic agreement to develop and commercialise innovative therapies

15 February 2018

Ipsen delivers strong 2017 results with 21.1% sales growth and Core operating margin increase of 3.4 points and expects significant further growth in sales and margin in 2018

FY 2017 – Results announcement

FY 2017 – Results presentation
07 February 2018

Ipsen announces eight oral presentations from its Neurosciences portfolio at the 10th World Congress for Neurorehabilitation (WCNR)

29 January 2018

Dr Sotirios G. Stergiopoulos appointed as Ipsen Chief Medical Officer

16 January 2018

Ipsen announces 13 posters and 1 oral presentation at the 2018 ASCO Gastrointestinal Symposium

16 January 2018

Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma

12 January 2018

Ipsen appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America

02 January 2018

Ipsen announces it is no longer eligible for the PEA-PME scheme

09 December 2017

Ipsen announces its corporate agenda for 2018

29 November 2017

Ipsen announces publication in Neurology of results of two studies demonstrating the efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with lower limb spasticity

26 October 2017

Ipsen delivers strong sales growth of 22.6% for the third quarter of 2017 and confirms full year guidance

YTD 2017 – Sales announcement
16 October 2017

Ipsen announces that phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma

19 September 2017

Ipsen receives approval from European Commission for Xermelo® (telotristat ethyl) for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

18 September 2017

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome

09 September 2017

Ipsen and Exelixis announce results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma at ESMO 2017

08 September 2017

Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx® (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults

04 September 2017

Ipsen announces 16 abstract presentations of oncology portfolio at European Society of Medical Oncology congress

16 August 2017

Exelixis submits U.S. supplemental new drug application for Cabometyx®(Cabozantinib) for the treatment of previously untreated advanced kidney cancer

27 July 2017

Ipsen delivers strong sales growth of 18.8% in the first half of 2017 and upgrades its guidance for full year 2017

H1 2017 – Results announcement

H1 2017 – Results presentation
21 July 2017

Ipsen receives positive CHMP opinion for approval of Xermelo® (telotristat ethyl), for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

10 July 2017

Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETY or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma.

03 July 2017

Somatuline® Autogel® 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors

30 June 2017

Ipsen announces co-promotion agreement with Saol Therapeutics to promote Dysport® (abobotulinumtoxinA) in the United States

19 June 2017

Ipsen and its partner Exelixis announce independent radiology committee review confirms results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

16 June 2017

Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in adults

15 June 2017

Ipsen’s Partner Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors.

08 June 2017

Ipsen initiates share buy-back program to cover its free performance share allocation plan

07 June 2017

Combined Shareholders’ Meeting of 7 June 2017

07 June 2017

Combined Shareholders’ Meeting of IPSEN S.A. held on 7 June 2017

Combined-Shareholders-Meeting-of-IPSEN-S.A.-held-on-7-June-2017
01 June 2017

Ipsen announces new data to be presented at ASCO in line with its continued commitment to Oncology research

11 May 2017

Ipsen presents its new strategy and improved 2020 financial targets

08 May 2017

Ipsen completes acquisition of select Consumer Healthcare products from Sanofi

27 April 2017

Ipsen reports strong first quarter 2017 sales growth of 19,1%

Q1 2017 – Sales announcement
25 April 2017

Resolutions submitted to Ipsen’s Shareholders’ Meeting on June 7, 2017

14 April 2017

Ipsen appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer

03 April 2017

Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals

28 March 2017

The Ipsen Group publishes its 2016 Registration Document

13 March 2017

Ipsen announces MHRA approval of new indication for Decapeptyl® for the treatment of pre-menopausal women with early stage breast cancer

09 March 2017

Ipsen announces data presentations of lanreotide (Somatuline® Autogel®), telotristat ethyl and the investigational compound 177Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS) 2017 conference

02 March 2017

Ipsen appoints Benoit Hennion as Executive Vice President and President, Primary Care

01 March 2017

Ipsen’s Partner Lexicon Pharmaceuticals Announces That FDA Approves Lexicon Drug Xermelo™ (Telotristat ethyl) 250 mg as First and Only Oral Treatment for Carcinoid Syndrome Diarrhea in Cancer Patients with Metastatic Neuroendocrine Tumors.

27 February 2017

Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.

23 February 2017

Ipsen delivers strong 2016 results and expects further sales growth and margin enhancement for 2017

FY 2016 – Results announcement

FY 2016 – Results presentation
13 February 2017

Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi

31 January 2017

Ipsen to acquire Primary Care platform in Italy from Akkadeas Pharma

20 January 2017

Ipsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises

09 January 2017

Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals

21 December 2016

Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada

13 December 2016

Ipsen announces its corporate agenda for 2017

12 December 2016

Claude Bertrand to step down as Executive Vice President, R&D, Chief Scientific Officer of Ipsen

26 October 2016

Ipsen reports 12.2% sales growth for the third quarter of 2016 and raises full year guidance

YTD 2016 – Sales announcement
20 October 2016

The 2016 Georges Mathé Prize recognizes research on the immunological determinants of the response to breast cancer treatment

30205349966_1ac8f6f57f_k.jpg
10 October 2016

Ipsen and its partner Exelixis announce positive results from phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma presented at the European Society for Medical Oncology (ESMO) 2016 congress

07 October 2016

Ipsens’ partner, Exelixis, announced phase 1 trial results for cabozantinib in combination with nivolumab in advanced genitourinary tumors

27 September 2016

Ipsen announces data presentations of cabozantinib (Cabometyx™), lanreotide (Somatuline® Autogel®) and telotristat ethyl* at the European Society for Medical Oncology (ESMO) 2016 congress

14 September 2016

European Commission approves Ipsen’s Cabometyx™ (cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

01 August 2016

Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for injection for the treatment of Lower Limb Spasticity in children aged two and older.

28 July 2016

Supplemental Application Filed for Somatuline® in Japan for Additional Indication of Neuroendocrine Tumors

28 July 2016

Ipsen’s First Half 2016 Results

H1 2016 – Results announcement

H1 2016 – Results presentation
23 July 2016

Ipsen annonce l’autorisation par la FDA de Dysport® (abobotulinumtoxinA) injection dans le traitement de la spasticité des membres inférieurs chez l’enfant âgé de 2 ans et plus

22 July 2016

Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx™ (cabozantinib) for the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

18 July 2016

Ipsen announces the acceptance by the European Medicines Agency of the marketing authorization application for telotristat etiprate to treat carcinoid syndrome caused by neuroendocrine tumors, in combination with somatostatin analogues

11 July 2016

David Meek appointed as Chief Executive Officer of Ipsen

08 June 2016

Ipsen successfully issues inaugural €300 million 7-year Notes

05 June 2016

Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CABOMETYX™ (cabozantinib) tablets in advanced renal cell carcinoma at 2016 ASCO annual meeting

05 June 2016

The Ipsen Group launches an employee shareholding plan

04 June 2016

Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO

31 May 2016

Combined Shareholders’ Meeting of 31 May 2016

31 May 2016

Eugenia Litz is appointed as Vice President Investor Relations of Ipsen

30 May 2016

Ipsen’s partner, Lexicon, announced FDA Priority Review of new drug application for telotristat etiprate for the treatment of carcinoid syndrome

22 May 2016

Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma

16 May 2016

Ipsen partners with IMCB to advance understanding and research of botulinum neurotoxin biology

02 May 2016

Oncodesign and Ipsen enter into a strategic partnership in oncology and Oncodesign joins Ipsen’s Paris-Saclay Campus

27 April 2016

Ipsen’s first quarter 2016 sales up 4.7%

Q1 2016 – Sales announcement
25 April 2016

Probi and Ipsen sign extensive Primary Care distribution agreement for probiotic LP299V®, Lactobacillus plantarum 299v

25 April 2016

Ipsen is pleased to announce that its partner Exelixis obtained FDA Approval of CABOMETYX™ (cabozantinib) tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy

04 April 2016

Dassault Systèmes and Ipsen sign collaborative agreement to develop innovative programs to support Ipsen’s drug discovery

30 March 2016

The Ipsen Group publishes its 2015 Registration Document

PR-DDR
07 March 2016

Ipsen and PeptiMimesis announce a research partnership in oncology

01 March 2016

Exelixis and Ipsen enter into exclusive licensing agreement to commercialize and develop novel cancer therapy Cabozantinib in regions outside the United States, Canada and Japan

01 March 2016

Ipsen’s 2015 results and 2016 financial objectives

FY 2015 – Results announcement

FY 2015 – Results presentation
16 February 2016

Ipsen enters into a licensing agreement with 3B Pharmaceuticals to develop novel radiopharmaceuticals in oncology

15 February 2016

Changes to Ipsen corporate governance

25 January 2016

Ipsen announces publication in Pediatrics of the results of the phase III randomized study showing the efficacy and safety of Dysport® (abobotulinumtoxinA) in children with dynamic equinus foot deformity due to cerebral palsy

05 January 2016

Ipsen and Galderma expand current distribution agreement for Dysport® in aesthetic indications to some key Asia-Pacific territories

16 December 2015

Ipsen announces its corporate agenda for 2016

30 November 2015

Ipsen’s partner Lexicon announced that Telotristat Etiprate had achieved positive top-line results in second phase 3 clinical trial

18 November 2015

Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology

28 October 2015

Ipsen: sales in the 3rd quarter and first nine months of 2015

27 October 2015

Telesta Therapeutics and Ipsen announce exclusive license agreement for MCNA for the treatment of non-muscle invasive bladder cancer in major ex-United States territories

25 October 2015

Ipsen and EpiVax collaborate to produce next generation botulinum toxins

21 October 2015

Ipsen presents additional results from a Phase III clinical trial of the investigational use of Dysport® in children with spastic equinus foot deformity due to cerebral palsy

18 October 2015

Ipsen’s partner Lexicon announced at the 2015 Neuroendocrine Tumor Society Annual Symposium (Austin, Texas) that telotristat etiprate was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study in cancer patients whose carcinoid syndrome was not adequately controlled by somatostatin analog (SSA) therapy.

30 September 2015

Ipsen announces release of an additional batch of Increlex® in the U.S.

30 September 2015

Stéphane Bessette is appointed Executive Vice President, Human Resources of Ipsen

28 September 2015

Ipsen’s partner Lexicon presents phase III TELESTAR study data at ECC 2015 (Vienna, Austria) showing that telotristat etiprate reduces the average number of daily bowel movements in patients with carcinoid syndrome not adequately controlled by somatostatin analogues.

30 August 2015

Ipsen announces publication in The Lancet Neurology of the results of the phase III randomized study (NCT01313299) showing efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with upper limb spasticity (ULS)

02 August 2015

Ipsen’s partner, Lexicon Pharmaceuticals, announces positive results from TELESTAR phase 3 study showing that telotristat etiprate is effective in the treatment of carcinoid syndrome caused by neuroendocrine tumors not adequately controlled by somatostatin analogs

30 July 2015

Ipsen: 2015 half-year results

30 July 2015

Ipsen: 2015 half-year results and 2015 objectives

15 July 2015

Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for injection in the treatment of upper limb spasticity in adults in the United States

01 July 2015

Ipsen provides an update on 2020 strategy and outlook at Investor Day

02 June 2015

Ipsen initiates a share buyback program Shares will be cancelled to compensate dilution resulting from its free share plans

01 June 2015

Ipsen confirms its eligibility for PEA-PME

28 May 2015

Combined Shareholders’ Meeting of IPSEN S.A. held on 27 May 2015

27 May 2015

Combined Shareholders’ Meeting of 27 May 2015

18 May 2015

Ipsen strengthens its presence in the oncology field with the acquisition of OctreoPharm Sciences, a company developing innovative radiopharmaceuticals for the diagnosis and treatment of neuroendocrine tumours

28 April 2015

Ipsen reports strong sales growth in Q1 2015 and raises guidance for the year

15 April 2015

Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in prostate cancer

07 April 2015

Ipsen and Hannover Medical School start joint research in recombinant botulinum neurotoxins for targeted secretion inhibitors

31 March 2015

Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub in the USA, to expand U.S. presence

31 March 2015

Ipsen expands ties to Harvard University with signing of a new Research Alliance Agreement

30 March 2015

The Ipsen Group publishes its 2014 Registration document

03 March 2015

Precisions concerning the resupply of Increlex® in the U.S.

02 March 2015

Ipsen’s 2014 results and 2015 financial objectives

01 March 2015

Dominique Laymand is appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer

01 March 2015

Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015

23 February 2015

Ipsen enters into option agreement to acquire Canbex Therapeutics

02 February 2015

Ipsen: sales in the fourth quarter and full year 2014

25 January 2015

Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults

06 January 2015

Ipsen announces its corporate agenda for 2015

15 December 2014

François Garnier appointed Executive Vice President, General Counsel of Ipsen

15 December 2014

Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors

11 December 2014

Ipsen announces that the International Breast Cancer Study Group (IBCSG) presented phase 3 results evaluating the use of ovarian suppression to adjuvant treatment with tamoxifen

27 November 2014

Ipsen announces FDA acceptance of filing for Dysport® in the treatment of upper limb spasticity in adult patients

19 November 2014

Ipsen and CNRS create the “Archi-Pex” joint research and innovation lab, in collaboration with the University of Rennes 1 and CEA

17 November 2014

Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences

05 November 2014

Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus

28 October 2014

Ipsen: sales in the 3rd quarter and first nine months of 2014

21 October 2014

Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate

09 October 2014

Aymeric Le Chatelier joins Ipsen as Executive Vice President, Chief Financial Officer

09 October 2014

Ipsen announces positive results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered by subcutaneous route to prostate cancer patients

01 October 2014

Susheel Surpal steps down as Executive Vice President, Chief Financial Officer of Ipsen to pursue other opportunities

26 September 2014

Ipsen presents preliminary results of exploratory proof-of-concept study with tasquinimod in four advanced tumor types at the ESMO 2014 Congress

31 August 2014

Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review and in Europe

28 August 2014

Ipsen: 2014 half-year results and 2014 objectives

26 August 2014

Ipsen North America Announces Second Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2014

16 July 2014

New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors

10 July 2014

Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe

30 June 2014

Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

04 June 2014

Ordinary Shareholders’ Meeting of 4 June 2014

1 – Preliminary notice to the Meeting – published in the French BALO (French only) – AGM 4 june 2014

2 – Information voting rights-shares – AGM 4 june 2014

3 – Shareholders’ meeting notice – published in the French BALO (French only) – AGM 4 june 2014

5 – Voting or proxy form – AGM 4 june 2014

6 – Availability and consultation of preparatory documentation for the AGM – AGM 4 june 2014

7 – Registration Document 2013 – AGM 4 june 2014

10 – Press Release post AGM – AGM 4 june 2014
03 June 2014

Ordinary Shareholders’ Meeting of IPSEN S.A. held on 4 June 2014

04-06-2014-PR-general-shareholders-meeting-2014-EN
12 May 2014

Ipsen announces a step forward in the resupply of Increlex® in the U.S.

29 April 2014

Ipsen’s first quarter 2014 sales

27 April 2014

Registration Document 2013

11 April 2014

Ipsen announces a first set of results on positive phase III clinical study of Dysport® in the treatment of adults suffering from Upper Limb Spasticity at the 8th World Congress for NeuroRehabilitation in Istanbul

10 April 2014

The Fondation Ipsen celebrates its 30th anniversary with a prestigious conference on the perspectives of cancer research, “Biology viewed through the prism of cancer”, attended by 8 Nobel Prize laureates and the greatest scientists in biomedical research

08 April 2014

Ipsen eligible for PEA-PME and included in CAC® PME index by Euronext

19 March 2014

Ipsen announces that its controlling shareholder, Mayroy, sold approximately 7% of Ipsen’s share capital via private placement

17 March 2014

Ipsen announces positive results from phase IIa clinical study of Dysport® in the treatment of patients with Neurogenic Detrusor Overactivity (NDO)

27 February 2014

Ipsen’s 2013 results and 2014 financial objectives

06 February 2014

Ipsen announces positive top line results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered subcutaneously in patients with prostate cancer

04 February 2014

Ipsen announces clinical results of Dysport® Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW

21 January 2014

Ipsen implements a new governance in the United States to prepare for the launch of Somatuline® in oncology

16 January 2014

Ipsen announces at ASCO GI that ELECT® clinical trial of Somatuline® in the control of symptoms in GEP-NET 1 patients with carcinoid syndrome met its primary endpoint

13 January 2014

Ipsen and GW Pharmaceuticals plc enter into agreement for Ipsen to promote and distribute Sativex® in Latin America

13 January 2014

Ipsen to set up its own US oncology team for Somatuline® Depot® (lanreotide) Injection in neuroendocrine tumors

09 January 2014

Jonathan Barnsley joins Ipsen as Executive Vice President, Technical operations

22 December 2013

Ipsen announces its corporate agenda for 2014

17 December 2013

Ipsen prepares for the resupply of Increlex® in Europe

17 December 2013

Ipsen and Mayoly Spindler enter into cross- promotion agreement for primary care activities in France

16 December 2013

Ipsen announces positive initial results from the international double-blind clinical phase III study of Dysport ® in the treatment of Adults suffering from Upper Limb Spasticity

11 December 2013

Dominique Brard joins Ipsen as Executive Vice President, Human Resources

02 December 2013

The 13th Colloque Médecine et Recherche of the Fondation Ipsen in the Endocrinology series: “Brain Crosstalk in Puberty and Adolescence”

21 November 2013

The 22nd Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen has been awarded to Jean Decety (University of Chicago, Chicago, USA)

05 November 2013

Ipsen initiates a share buy-back program to partially cover its restricted share plans

29 October 2013

Ipsen: sales in the third quarter and first nine months of 2013

16 October 2013

The 8th Cell Press / Days of Molecular Medicine Global Foundation / Fondation Ipsen meeting in the Exciting Biologies series: “Biology of boundaries”

08 October 2013

Active Biotech receives tasquinimod milestone payment from Ipsen for 10TASQ10 study

05 October 2013

PeptiDream and Ipsen expand the scope of their collaboration for discovery of peptide drugs to treat serious endocrinologic disease

01 October 2013

New organization project and composition of the Executive Committee to accelerate the implementation of Ipsen’s strategy

27 September 2013

Ipsen announces that results from CLARINET® Phase III clinical trial presented at the 2013 European Cancer Congress showed the antiproliferative effect of Somatuline® (lanreotide) 120 mg injection in the treatment of non-functioning gastroentero and pancreatic neuroendocrine tumors (“GEP-NETs”)

25 September 2013

Ipsen to relocate US R&D activities to Cambridge, MA in 2014

16 September 2013

Ipsen announces positive top line results from phase III ELECT® study of Somatuline® in the control of symptoms in NET patients with a history of carcinoid syndrome

29 August 2013

Ipsen: 2013 half-year results and financial objectives

29 August 2013

Detailed results of the phase III CLARINET study at the European Cancer Congress 2013 on 28 September 2013

14 July 2013

Ipsen strengthens its neurology R&D capabilities with the acquisition of Syntaxin, a leader in recombinant botulinum toxin technology

14 July 2013

Ipsen announce a sponsored research agreement with Harvard Medical School to discover novel engineered botulinum toxins for serious neurologic diseases

10 July 2013

Ipsen announces positive results from phase III CLARINET study of Somatuline® Autogel® 120mg in gastrointestinal and pancreatic neuroendocrine tumors (“GEP-NETs”)

16 June 2013

“PRIMARYS” study Investigators observed clinically relevant results in an investigational Phase III study with Somatuline® Autogel® 120 mg in patients with acromegaly

13 June 2013

Ipsen reorganizes its US neurology platform and confirms its goal to become profitable in the US in 2014

30 May 2013

Combined Shareholders’ Meeting of IPSEN S.A. held on 31 May 2013

29 May 2013

24 th Neuronal Plasticity Prize of the Fondation Ipsen: Tim V.P. Bliss, Richard G. Morris and Yadin Dudai awarded for their works in the domain of “Mechanisms of memory”

01 May 2013

Combined Shareholders’ Meeting of 31 May 2013

01 May 2013

Availability of documentation for the Shareholders’ Meeting

24 April 2013

Ipsen’s first quarter 2013 sales

24 April 2013

Active Biotech and Ipsen update the analysis plan for the 10TASQ10 trial evaluating tasquinimod in the treatment of prostate cancer

24 April 2013

Ipsen expects Increlex® supply interruption due to supplier manufacturing issues

23 April 2013

Combined Shareholders’ Meeting of Ipsen on 31 May 2013: Proposals of renewal of the terms of office of two Directors and appointment of a new Director

22 April 2013

The 21st Colloque Médecine et Recherche of the Fondation Ipsen in the Neurosciences series: “New frontiers in social neuroscience”

09 April 2013

Pepti Dream and Ipsen enter into a collaboration for advancing drug discovery efforts for peptides to treat serious disease

08 April 2013

Ipsen’s Dysport® approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics Canada

26 March 2013

The Ipsen Group publishes its 2012 Registration document

DDR_2012_EN
20 March 2013

Ipsen and Inspirations Biopharmaceuticals announce closing of the sale of OBI-1 to Baxter International

26 February 2013

Ipsen’s 2012 results and 2013 financial objectives

26 February 2013

Christel Bories joins Ipsen as Deputy Chief Executive Officer

19 February 2013

Ipsen and Inspiration Biopharmaceuticals announce closing of the IB1001 sale to Cangene Corporation

06 February 2013

Eziclen® / Izinova® a new product for bowel cleansing successfully completed European decentralised registration procedure

05 February 2013

Ipsen and Inspiration Biopharmaceuticals enter into an Asset Purchase Agreement with Cangene Corporation on IB1001

23 January 2013

Ipsen and Inspiration Biopharmaceuticals enter into an Asset Purchase Agreement with Baxter International on OBI-1

16 January 2013

Teijin Pharma to launch Ipsen’s Somatuline® subcutaneous injection in the treatment of acromegaly and pituitary gigantism in Japan

02 January 2013

Ipsen’s corporate agenda for 2013

17 December 2012

Oncodesign and the Laboratory for Neurobiology and Gene Therapy at the KU Leuven enter into a research collaboration for advancing drug discovery efforts with Ipsen in Parkinson’s disease

09 December 2012

Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer

04 December 2012

The 12nd Colloque Médecine et Recherche of the Fondation IPSEN in the Endocrinology series: “Hormones, intrauterine health and programming”

03 December 2012

The 21th Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen has been awarded to Cathy Price (University College London, London, UK)

02 December 2012

Ipsen and Galderma increase their collaboration for Dysport® in new territories

19 November 2012

Ipsen and Inspiration Biopharmaceuticals announce that OBI-1 has received Fast Track designation from FDA for acquired hemophilia A

18 November 2012

The 2012 Fondation Ipsen Longevity Prize has been awarded to Prof. Linda Fried for her outstanding work on the frailty syndrome

30 October 2012

Ipsen’s hemophilia partner, Inspiration Biopharmaceuticals, seeks Chapter 11 protection

28 October 2012

Ipsen’s third quarter and first nine months 2012 sales

24 October 2012

The 2nd meeting of the series Days of Molecular Medicine – « The Translational Science of Rare Diseases : From Rare to Care »

18 October 2012

Ipsen to initiate a proof-of-concept study with tasquinimod in additional cancer indications

02 October 2012

Ipsen provides update on recent agreement with Inspiration

02 October 2012

Ipsen initiates a phase II “Switch maintenance” trial in metastatic castrate-resistant prostate cancer with tasquinimod

30 September 2012

Tasquinimod Biomarker Phase II data presented at ESMO 2012

19 September 2012

The 11th Endocrine Regulation Prize of the Fondation Ipsen is awarded to Dr Jeffrey M. Friedman

09 September 2012

Ipsen maintains Increlex® (mecasermin [rDNA origin] injection) supply in the US

27 August 2012

Ipsen’s half-year 2012 Results

20 August 2012

Ipsen and Inspiration Biopharmaceuticals renegotiate strategic partnership agreement

24 July 2012

23rd Neuronal Plasticity Prize of the Fondation Ipsen: Catherine Dulac, Michael Meaney and J. David Sweatt awarded for their pioneer works in the domain of “Epigenetic and brain function”

10 July 2012

Ipsen decides to retain the Dreux-based primary care industrial facility within the Group’s scope

09 July 2012

Ipsen’s partner Inspiration Biopharmaceuticals announces hold of phase III clinical trials evaluating IB1001 for the treatment and prevention of hemophilia B

28 June 2012

Ipsen’s Somatuline® receives marketing approval in Japan for the treatment of acromegaly and pituitary gigantism

03 June 2012

Active Biotech’s and Ipsen’s Tasquinimod shows encouraging overall survival improvement in castrate resistant prostate cancer

31 May 2012

Combined Shareholders’ Meeting of IPSEN S.A. held on 1 June 2012

20 May 2012

600 Patients Recruited in Active Biotech’s and Ipsen’s tasquinimod Clinical Phase III Study

17 May 2012

Active Biotech and Ipsen to present Tasquinimod Phase II Overall Survival data at the 2012 ASCO Annual Meeting

10 May 2012

The 10th Endocrine Regulation Prize of the Fondation Ipsen is awarded to Paolo Sassone-Corsi

03 May 2012

Combined General Meeting of 1 June 2012

03 May 2012

Availability of preparatory documentation for the Shareholders’ Meeting

02 May 2012

Ipsen’s first quarter 2012 sales

24 April 2012

Ipsen pursues its development in the United States with the opening of its new commercial headquarters in New Jersey (NJ)

16 April 2012

Ipsen’s partner, Inspiration Biopharmaceuticals, announces US filing of Biologics License Application (BLA) for IB1001, a recombinant factor IX product for the treatment of hemophilia B

02 April 2012

The 20th Colloque Médecine et Recherche of the Fondation Ipsen in the Neurosciences series: “Programmed cells: from basic neuroscience to therapy”

01 April 2012

The Ipsen Group publishes its 2011 Registration document

28 February 2012

Ipsen’s 2011 results and 2012 objective

27 February 2012

The 27 th Colloque Médecine et Recherche of the Fondation Ipsen in the Alzheimer Disease series: “Proteopathic Seeds and Neurodegenerative Diseases”

23 February 2012

Active Biotech and Ipsen report Tasquinimod (TASQ) phase II long term safety data at the 27th European Association of Urology (EAU) Congress

01 February 2012

Ipsen’s fourth quarter and full year 2011 sales and other significant developments

26 January 2012

Ipsen acknowledges Tanakan® delisting in France

23 January 2012

Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement

22 January 2012

Fifth meeting in the “Biological Complexity” series jointly organised by the Fondation Ipsen and the Salk Institute for Biological Studies

04 January 2012

Oncodesign and Ipsen enter into a research collaboration for the development of new therapeutic agents against the LRRK2 Parkinson’s disease target

03 January 2012

Ipsen announces its corporate agenda for 2012

01 December 2011

The 20th Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen is awarded to Prof. Patricia K. Kuhl (University of Washington, Seattle, USA)

28 November 2011

The 11st Colloque Médecine et Recherche of the Fondation Ipsen in the Endocrinology series: “Multiple origins of sex differences in brain. Neuroendocrine functions and their pathologies.”

27 November 2011

Ipsen’s partner Inspiration Biopharmaceuticals announces the initiation of the second phase III pivotal clinical study of OBI-1 in congenital hemophilia A with inhibitors

22 November 2011

16th Longevity Prize of La Fondation Ipsen: Professor Thomas Kirkwood is awarded in recognition of his outstanding leadership in the domain of “Theoretical approach to the biology of longevity”

01 November 2011

Ipsen sells the North American development and marketing rights for Apokyn® to Britannia Pharmaceuticals, achieving a key milestone in the execution of its new North American strategy

26 October 2011

Ipsen’s first nine months of 2011 sales

19 October 2011

Syntaxin and Ipsen enter into a strategic agreement to develop novel botulinum-toxin therapeutics

02 October 2011

Ipsen’s partner, Inspiration Biopharmaceuticals, announces acceptance of European marketing authorization application for IB1001 for the treatment of hemophilia B

26 September 2011

Ipsen in-licenses from Photocure Hexvix®, the first approved & marketed drug for improved detection of bladder cancer, a key step in the surgical resection

29 August 2011

Appointments to Ipsen’s Executive Committee: Nathalie Joannes is nominated Executive Vice President, General Counsel and Susheel Surpal is nominated Executive Vice President, Chief Financial Officer

29 August 2011

Ipsen’s half-year 2011 Results

29 August 2011

Inspiration Biopharmaceuticals and Ipsen Expand their Partnership in Preparation for the Commercial Launch of Inspiration’s Hemophilia Pipeline in Europe

27 July 2011

Ipsen’s partner Inspiration Biopharmaceuticals announces data from OBI-1 pivotal stage program in Hemophilia at 23 rd ISTH congress

18 July 2011

22nd Neuronal Plasticity Prize of the Fondation Ipsen: Helen J. Neville, Isabelle Peretz and Robert J. Zatorre awarded for their pioneering research into the domain of “Music and Brain Plasticity”

11 July 2011

Ipsen and Institut de cancérologie Gustave Roussy enter into a partnership agreement

11 July 2011

Renewal of agreement between Ipsen and the Salk Institute supports cutting-edge research

08 June 2011

Increase focus, invest to grow, leverage footprint: Ipsen’s new strategy

05 June 2011

Ipsen announces discontinuation of the development of Irosustat in monotherapy

26 May 2011

Change within Ipsen’s Executive Committee

26 May 2011

Combined Shareholders’ Meeting of Ipsen S.A. held on 27 May 2011

26 May 2011

Combined General Meeting of 27 May 2011

10 May 2011

Appointment of Etienne de Blois as Ipsen’s Executive Vice-President, Human Resources

09 May 2011

The 26th Colloque Médecine et Recherche of the Fondation Ipsen in the series Alzheimer Disease : “Protein Quality Control in Neurodegenerative Diseases”

03 May 2011

Combined Shareholders’ Meeting : Availability of preparatory documentation

02 May 2011

Ipsen’s first quarter 2011 sales

01 May 2011

Changes within Ipsen’s Executive Committee

26 April 2011

The Ipsen Group publishes its 2010 Registration document

18 April 2011

The 19th Colloque Médecine et Recherche of the Fondation Ipsen in the Neuroscience series: “Epigenetics, Brain and Behavior

17 April 2011

Active Biotech and Ipsen enter into a broad partnership for the co-development and commercialization of TASQ in uro-oncology

08 March 2011

The FDA approves Somatuline® Depot (lanreotide) Injection Extended Dosing Interval as part of Ipsen’s Prior Approval Supplement application

01 March 2011

Ipsen’s 2010 results and 2011 sales objective

24 February 2011

Ipsen and bioMérieux enter into a broad partnership in personalized medicine

02 February 2011

Ipsen’s partner Inspiration Biopharmaceuticals announces non-inferiority of IB1001, its recombinant factor IX for Hemophilia B

01 February 2011

Ipsen’s fourth quarter and full year 2010 sales and other significant developments

22 December 2010

Ipsen announces its corporate agenda for 2011

14 December 2010

Ipsen closes its BIM 23A760 trials

01 December 2010

The 19th Jean-Louis Signoret Neuropsychology Prize of the Fondation Ipsen is awarded to Prof. Giacomo Rizzolati (University of Parma, Parma, Italy)

29 November 2010

10th Colloque Médecine et Recherche of the Fondation Ipsen in the Endocrinology series: “Multi-system Endocrine Disruption”

22 November 2010

Professor Judith Campisi is awarded in recognition of the outstanding work she has been carrying in the domain of longevity, senescence and cancer

18 November 2010

Ipsen’s partner Inspiration Biopharmaceuticals announces the treatment of the first patient in phase III pivotal study of OBI-1 for acquired hemophilia A

27 October 2010

Ipsen first’s nine months of 2010 Sales

18 October 2010

OBI-1 Receives Orphan Drug Designation in Europe

10 October 2010

Ipsen sells its shares in PregLem Holding SA to Gedeon Richter Plc

10 October 2010

Ipsen’s Board of Directors announces Jean-Luc Bélingard’s departure and the appointment of Marc de Garidel as new Chairman and CEO

10 October 2010

“Cell Biology in Recognition”

02 September 2010

Santhera and Ipsen Enter into Licensing Agreement Santhera and Ipsen Enter into Licensing Agreement in Parkinson’s Disease

30 August 2010

Ipsen’s Half-year 2010 Results

25 June 2010

Ipsen’s partner Roche confirms the promising efficacy profile of Taspoglutide

21 June 2010

Encouraging results of GuidAge®, large scale European trial conducted in the prevention of Alzheimer’s Dementia

17 June 2010

Ipsen’s partner Roche announces amendment of the trial protocols for the taspoglutide phase III programme

16 June 2010

OBI-1 developed by Ipsen and Inspiration has obtained a positive opinion for the orphan drug status in Europe

08 June 2010

Implementation of a Sponsored Level I American Depositary Receipt (ADR) program: A new step in Ipsen’s development in the United States

27 May 2010

Combined Shareholders’ Meeting of Ipsen S.A. held on 28 May 2010

06 May 2010

Combined General Meeting on 28 May 2010 : Availability of preliminary documents

02 May 2010

Ipsen’s first quarter 2010 sales

28 April 2010

Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoint in a key phase III clinical trial

26 April 2010

Ipsen and Invida Enter into a Partnership for the Commercialization of Ipsen’s Specialty Care Drugs in South-East Asia

29 March 2010

Dicerna Pharmaceuticals and Ipsen enter into an exclusive research collaboration for the development of new therapeutic agents in endocrinology and oncology

23 March 2010

Update on Ipsen’s share capital structure

22 March 2010

GTx and Ipsen expand partnership

14 March 2010

Initiation of two phase II studies with Ipsen’s proprietary BIM 23A760 first-in-class chimeric compound in the treatment of acromegaly and carcinoid syndrome due to neuroendocrine tumors

11 March 2010

Ipsen grants Rhythm exclusive worldwide license for two programs in the field of metabolic disorders

04 March 2010

Launch by Menarini and Ipsen of ADENURIC® (febuxostat) in France for the treatment of chronic hyperuricemia in gout

28 February 2010

Ipsen’s 2009 results and objectives

03 February 2010

Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer

20 January 2010

Ipsen and Inspiration Biopharmaceuticals enter into partnership to create a world leading hemophilia franchise

16 December 2009

Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoints in two further head-to-head phase III studies with insulin glargine (Lantus®) and versus placebo in patients with high body mass index (BMI)

16 December 2009

Ipsen’s financial communication nominated to the “2009 Trophy of the Best Investor Relations” of Euronext

13 December 2009

Ipsen establishes optimal biological dose for BN83495 steroid sulphatase (STS) inhibitor in ER-positive metastatic breast cancer

08 December 2009

Ipsen announces its corporate agenda for 2010

01 December 2009

Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoints in head-to-head study with sitagliptin (Januvia®) and versus placebo

24 November 2009

Ipsen initiates an Advanced Endometrial Cancer program with BN83495, its first-in-class steroid sulfatase (STS) inhibitor

12 November 2009

Ipsen’s Decapeptyl® 6-month formulation receives marketing authorization in France for the treatment of locally advanced or metastatic prostate cancer

28 October 2009

Ipsen announces the launch of Dysport® (abobotulinumtoxinA) in the United States for the treatment of cervical dystonia

28 October 2009

Ipsen’s first nine months of 2009 sales and update of Group financial objectives

28 October 2009

Ipsen’s partner Roche announces that Taspoglutide meets its primary endpoint in the first phase III clinical trial

19 October 2009

Ipsen grants Menarini exclusive European licence rights to Adenuric® (febuxostat), its novel treatment for chronic hyperuricaemia in gout

12 October 2009

Ipsen and Debiopharm Group announce that Decapeptyl® (triptorelin embonate) 6-month successfully completes the European Decentralised Procedure for the treatment of locally advanced or metastatic prostate cancer.

08 October 2009

Ipsen acquires exclusive marketing rights of BLI-800 from Braintree for colonic cleansing before colonoscopy

07 October 2009

Ipsen and Spirogen redesign their collaboration for the development of SJG-136 (now SG2000)

21 September 2009

Appointment of Claude Bertand as Executive Vice President, Chief Scientific Officer of Ipsen. Jacques-Pierre Moreau is appointed Chief Scientific Advisor to the Executive Committee.

20 September 2009

AZZALURE® approved in Spain for Aesthetic Use in the Treatment of Glabellar Lines

14 September 2009

Encouraging preliminary new data available for the treatment of short stature children with low IGF-1 levels.

06 September 2009

Ipsen and Debiopharm conclude an exclusive worldwide license agreement for the development and commercialisation of the Ipsen’s proprietary CDC-25 inhibitor (IRC-083864 or Debio 0931), an anti-cancer agent. Debio 0931 has the potential to target major human cancers.

27 August 2009

Ipsen’s half year 2009 results

15 July 2009

Results of Phase I and Phase IIa clinical studies confirm the inhibitory effect of proprietary Ipsen’s BIM23A760 first-in-class “chimeric” compound on growth hormone, IGF-1 and prolactin levels

25 June 2009

Azzalure approved in Germany for Aesthetic Use in the Treatment of Glabellar Lines

14 June 2009

Ipsen and PHARNEXT conclude an exclusive research, development and marketing agreement

03 June 2009

Ipsen’s Annual Shareholders’ Meeting on June 4, 2009

03 June 2009

Annual general meeting

19 May 2009

Combined General Meeting on June 4, 2009 – Availability of preliminary documents

18 May 2009

Disclosure of trading in own shares

13 May 2009

Disclosure of trading in own shares

10 May 2009

Appointment of Jean-Christophe Tellier as President and General manager of Ipsen in North America

29 April 2009

FDA approves Dysport(TM) for therapeutic and aesthetic uses

27 April 2009

Ipsen’s first quarter 2009 sales and financial outlook for the full year

19 April 2009

Mise à disposition du document de référence 2008

13 April 2009

Update on Ipsen’s botulinum toxin type A product regulatory review status in the US

30 March 2009

AZZALURE® is approved in France for Aesthetic Use in the Treatment of Frown Lines

11 March 2009

AZZALURE® approved in the UK for Aesthetic Use in the Treatment of Glabellar Lines

01 March 2009

Ipsen’s full year 2008 results

23 February 2009

Christian de la Tour is promoted Chairman of Ipsen UK and Sean McKercher, Vice-President, Corporate Business Development

01 February 2009

The Health Authorities of 15 European countries give a collective green light to Azzalure® for the treatment of glabellar lines, paving the way for national marketing authorizations

27 January 2009

Ipsen announces the signature of a co-promotion agreement with Novartis for Exforge® in France

18 January 2009

“Creating the future: New challenges in biology and medicine”: Ipsen gathers a panel of world-renowned scientists

07 January 2009

Ipsen provides update on R&D pipeline and business opportunities at its Investor Day

06 January 2009

FDA’s first-cycle review of Reloxin® extended

04 January 2009

Ipsen announces its corporate agenda for 2009

28 December 2008

FDA issues Complete Response Letter to Ipsen for Dysport® Biologics License Application

11 December 2008

AFEP/MEDEF recommendations on compensation of executive directors

29 October 2008

Ipsen’s first nine months of 2008 sales and update of Group financial objectives

16 October 2008

Ipsen completes the acquisition of Tercica, Inc. in North America, the third of its three steps to globalize its fast growing specialist care business

29 September 2008

FDA’s first-cycle review of Dysport® to be completed by year-end: US launch of Dysport® on track

24 September 2008

Ipsen announces the filing of Decapeptyl® 6-month formulation for the treatment of locally advanced or metastatic prostate cancer in Europe

28 August 2008

Ipsen’s half year 2008 results and update on standalone financial objectives for the full year 2008

22 July 2008

Ipsen continues the acquisition process of Tercica so as to establish its global presence in endocrinology

16 July 2008

Ipsen completes purchase of all of OBI-1 assets from Octagen Corporation

20080717_closing_octagen1
30 June 2008

Ipsen completes purchase of Apokyn®, Vernalis US commercial operations and share subscription

09 June 2008

Roche moves investigational diabetes drug, Taspoglutide, into Phase III clinical trials

04 June 2008

Ipsen builds a fully fledged presence in North America, significantly enhancing its geographic footprint, global specialty portfolio and growth profile

03 June 2008

Annual general meeting

03 June 2008

Ipsen’s Annual Shareholders’ Meeting on 4 June 2008

01 June 2008

Ipsen and Spirogen’s SJG-136 shows encouraging results in the treatment of refractory solid tumours at ASCO

21 May 2008

Appointment of Gérard Picot as Vice President, Global Regulatory Affairs

18 May 2008

Ipsen and Medicis announce acceptance of Reloxin® BLA in aesthetics by FDA

04 May 2008

Adenuric® (febuxostat) receives marketing authorisation in the European Union

28 April 2008

Ipsen’s first quarter 2008 sales

31 March 2008

Appointment of Dominique Bridon, PhD as Vice President, Discovery

17 March 2008

Appointment of Frédéric Babin as Executive Vice President, Human Resources

16 March 2008

Ipsen and Medicis announce submission of Reloxin® BLA in aesthetics to the FDA

26 February 2008

Ipsen’s full year 2007 results and financial objectives for the full year 2008

24 February 2008

Toremifene citrate 80 mg meets primary and key secondary endpoints in phase III clinical trial in advanced prostate cancer patients on androgen deprivation therapy

20 February 2008

EMEA recommends marketing authorisation of Ipsen’s Adenuric® (febuxostat) for the treatment of chronic hyperuricaemia in gout

11 February 2008

Clinical update for Decapeptyl® 6-month formulation in advanced prostate cancer

30 January 2008

FDA accepts for filing a Biologics License Application (BLA) for Dysport® in cervical dystonia

10 January 2008

Ipsen and The Salk Institute Enter into Strategic Research Agreement

02 January 2008

Two years after its IPO, Ipsen enters the SBF 120 index

19 December 2007

Ipsen announces its corporate agenda for 2008

05 December 2007

Ipsen submits a Biologics License Application (BLA) in cervical dystonia to the FDA for Dysport®

05 December 2007

Ipsen grants Galderma exclusive rights to promote and distribute Dysport® in aesthetic medicine and dermatological indications in Brazil, Argentina and Paraguay

05 December 2007

Ipsen and Medicis announce submission of Reloxin® in aesthetics to the FDA

03 December 2007

Seventh Colloque Médecine et Recherche of La Fondation Ipsen in the Endocrinology series: “Hormones and Social Behaviour”

03 December 2007

New Collaboration between Ipsen and Erasmus MC in endocrinology

19 November 2007

Celera and Ipsen enter research collaboration to develop pharmacogenomic tests

30 October 2007

Ipsen and Debiopharm extend their agreement for the exclusive commercialization of Decapeptyl® (triptorelin pamoate) in Europe and certain other territories

16 September 2007

bioMérieux and Ipsen sign theragnostics agreement to develop companion test for New breast cancer treatment

16 September 2007

A major pharmaceutical company has taken an exclusive option to BA058, a compound licensed by Ipsen to Radius in 2005

30 August 2007

Somatuline® Depot receives marketing approval in the United States for the treatment of acromegaly

28 August 2007

Ipsen’s first half 2007 results and financial objectives for the full year 2007

22 August 2007

Ipsen transfers Ginkor Fort® marketing authorisations to GTF for France, Monaco and Andorra

08 August 2007

Increlex® receives marketing authorisation in the European Union

26 June 2007

Ipsen announces license agreement with PregLem SA in field of reproductive medicine

10 June 2007

Phase III clinical trial with 4-month long-acting formulation of triptorelin: Ipsen decides not to perform further administration

05 June 2007

Annual general meeting

05 June 2007

Ipsen’s Annual Shareholders’ Meeting on 6 June 2007

31 May 2007

Ipsen will invest €55 million and plans to create 85 new jobs in Dreux (France) by 2011

24 May 2007

Increlex® receives CHMP positive opinion for the treatment of severe primary IGF-1 deficiency

02 May 2007

Ipsen’s first quarter 2007 sales

01 May 2007

Combined general meeting on 6 June 2007: Availability of preliminary documents

05 April 2007

Ipsen appoints Sean McKercher as Vice President of Commercial Development in North America

02 April 2007

Appointment of Eric Drapé as Executive Vice President, Manufacturing and Supply Organisation

18 March 2007

Ipsen’s full year 2006 results

25 February 2007

Ipsen grants Galderma exclusive rights to develop, promote and distribute its botulinum toxin type A product for aesthetic indications in Europe and certain other territories

25 February 2007

Appointment of Stéphane Thiroloix as Executive Vice-President, Corporate Development

29 January 2007

Agreement between Ipsen and MSD for the co-marketing in France of AdrovanceTM for the treatment of postmenopausal osteoporosis

23 January 2007

Ipsen strikes alliance with the Erasmus University Medical Centre Rotterdam

14 January 2007

FDA accepts for filing a New Drug Application (NDA) for Somatuline® Autogel® – Somatuline® Autogel® now available in Canada

13 December 2006

Initiation of phase III clinical trials with Decapeptyl®’s 4-month sustained release formulation

18 October 2006

Ipsen has noted the publication of the recommendations issued by the French Haute Autorité de Santé

15 October 2006

Ipsen and Tercica Complete Worldwide Strategic Collaboration Agreement in Endocrinology

01 October 2006

EMEA’s validation of febuxostat’s Marketing Authorization Application in the European Union

29 September 2006

Ipsen’s first nine months of 2006 sales

06 September 2006

Ipsen and GTx enter into partnership agreement for the European rights of Acapodene®

05 September 2006

Ipsen’s first half 2006 results

18 July 2006

Roche exercises its option on Ipsen’s anti-diabetic medicine for type 2 diabetes

18 July 2006

Ipsen and Tercica to enter into worldwide strategic collaboration in endocrinology

11 July 2006

Medicis and Ipsen decide to focus partnership for Reloxin® exclusively on USA, Canada and Japan

11 June 2006

Type 2 diabetes therapy: Ipsen is currently testing an innovative sustained release formulation of its GLP-1 analogue based on its proprietary drug delivery system technologies

01 June 2006

Annual general meeting

01 June 2006

Ipsen’s Annual Shareholders’ Meeting on 2 June 2006

18 April 2006

David Schilansky joined Ipsen as Investor Relations Officer

15 April 2006

Ipsen extends the deadline for entering into its European agreement with Medicis

19 March 2006

Reloxin® agreement between Ipsen and Medicis becomes effective

16 March 2006

Ipsen announces 26.4% increase in 2005 consolidated net profit

12 March 2006

Ipsen chooses Medicis to promote and distribute Ipsen’s botulinum toxin product to the aesthetic market

06 February 2006

Jean-Luc Bélingard, member of the Board of Directors of Inserm

31 January 2006

Ipsen reports full-year sales growth of 7.4% in the year ended 31 December 2005 (unaudited)

Contact us

Ioana Piscociu Senior Manager, Global Media Relations +33 6 69 09 12 96
Craig Marks Vice President, Investor Relations +44 7584 349 193
© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023